Skip to content

Effect of Branched-chain Amino Acid Supplementation and Exercise on Muscle Quantity and Quality in Cirrhosis

Effect of Branched-chain Amino Acid Supplementation and Exercise on Quadriceps Muscle Quantity and Quality in Patients With Cirrhosis as Assessed by Ultrasonography

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06088550
Enrollment
220
Registered
2023-10-18
Start date
2020-11-01
Completion date
2022-12-30
Last updated
2024-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Atrophy

Brief summary

Introduction: Ultrasound can be used to monitor muscle mass during interventional approaches in patients with liver cirrhosis. The aim: To investigate the effect of branched-chain amino acid (BCAA) supplementation and/or muscle exercise on ultrasound-measured quadriceps muscle thickness and echo intensity, as well as on muscle strength, performance, and nutritional assessment in patients with cirrhosis. Patients & Methods: This is a randomized controlled study that included 220 liver cirrhosis patients with Child-Pugh B & C classes. They were randomized into a control group comprising 55 patients who received only the standard care, and interventional groups comprising 165 patients equally distributed into three groups, they received in addition to standard care, BCAA, programmed exercise, or BCAA and programmed exercise respectively. At baseline and after 28 days, all participants were subjected to ultrasound-measured quadriceps muscle thickness and echo intensity, in addition to handgrip strength, short physical performance battery (SPPB), anthropometric measures, hematological and biochemical assessment, MELD score measurement, nutritional assessment using 7- subjective global assessment score (SGA).

Detailed description

This is an open, 4-arm parallel, randomized controlled trial conducted on cirrhotic patients All eligible patients received instructions of standard care that includes standard diet and non-exercise activity thermogenesis (NEAT), then the patients were randomly assigned in an allocation ratio of approximately 1:1:1:1; group 1= control received the standard care only, and three intervention groups; group 2 received added 10 gm/day branched-chain amino acid (BCAA) (manufactured by Dulex lab company). Group 3 received added home-based exercise comprising both aerobic and resistance exercises, and finally, group 4 received added both BCAA and home-based exercise. All patients were subjected to the following at the baseline and after 28 days: 1. thorough medical history 2. Complete clinical examination including BP, middle upper arm circumference (MUC), and body mass index (BMI) using the dry weight. 3. The nutritional status assessment using the 7-point Subjective Global Assessment (SGA) score, 4. Assessment of their physical fitness using the short physical performance battery test (SPPB) score. 5. Assessment of muscle strength using handgrip strength using a digital dynamometer (Model: 12-0286). 6. Routine labs including complete blood count (CBC), liver function, kidney function, and electrolytes, FBG 7. Calculation of Child-Pugh & MELD scores. 8. Ultrasound assessment of quadriceps muscle thickness and echogenicity

Interventions

OTHERhome-based graded exercise program

home-based graded exercise program comprises both aerobic and resistance exercise. The exercise was done by the patients themselves aided by a physiotherapist, a nurse or patients' relatives

DIETARY_SUPPLEMENTBCAA

a branched-chain amino acid (BCAA) formula: taken by oral route in the form of 2 scoops of Protofit BCAA daily on 200 cc water, (manufactured by Dulex lab company). Each scoop contains 5 gm BCAA (2.5 gm leucine, 1.25 gm isoleucine & 1.25 gm valine).

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Cirrhotic patients with moderate and marked liver impairment

Exclusion criteria

* cirrhotic patients with Child-Pugh class A, patients with acute liver cell failure or malignancies, associated other end-organ failure, and vitally unstable patients.

Design outcomes

Primary

MeasureTime frameDescription
a change from baseline of muscle quantity28 daysassessed by ultrasound quadriceps muscle thickness
a change from baseline of muscle strength28 daysassessed by handgrip strength
a change from baseline of muscle performance28 daysassessed by the short physical performance battery test (SPPB)
a change from baseline of muscle quality28 daysassessed by ultrasound quadriceps muscle echo intensity

Secondary

MeasureTime frameDescription
a change from the baseline of liver enzymes28 daysassessed by laboratory assessment of liver enzymes
a change from the baseline of nutritional status28 daysassessed by 7-point Subjective Global Assessment (SGA) score
a change from the baseline edema28 daysassessed by clinical grading
a change from the baseline of BP28 daysassessed by measuring BP
a change from the baseline of MELD score28 daysassessed by calculating MELD score at baseline and after 28 days
a change from the baseline of ascites28 daysassessed by subjective clinical grading
a change from the baseline of hematological parameters28 daysassessed by CBC

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026